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Melanomas are highly radioresistant tumors, mainly due to efficient DNA double-strand break (DSB) repair. Dbait
(which stands for DNA strand break bait) molecules mimic DSBs and trap DNA repair proteins, thereby inhibiting
repair of DNA damage induced by radiation therapy (RT). First, the cytotoxic efficacy of Dbait in combination with
RT was evaluated in vitro in SK28 and 501mel human melanoma cell lines. Though the extent of RT-induced
damage was not increased by Dbait, it persisted for longer revealing a repair defect. Dbait enhanced RT efficacy
independently of RT doses. We further assayed the capacity of DT01 (clinical form of Dbait) to enhance efficacy of
“palliative” RT (10 × 3 Gy) or “radical” RT (20 × 3 Gy), in an SK28 xenografted model. Inhibition of repair of RT-
induced DSB by DT01 was revealed by the significant increase of micronuclei in tumors treated with combined
treatment. Mice treated with DT01 and RT combination had significantly better tumor growth control and longer
survival compared to RT alone with the “palliative” protocol [tumor growth delay (TGD) by 5.7-fold; median
survival: 119 vs 67 days] or the “radical” protocol (TGD by 3.2-fold; median survival: 221 vs 109 days). Only animals
that received the combined treatment showed complete responses. No additional toxicity was observed in any
DT01-treated groups. This preclinical study provides encouraging results for a combination of a new DNA repair
inhibitor, DT01, with RT, in the absence of toxicity. A first-in-human phase I study is currently under way in the
palliative management of melanoma in-transit metastases (DRIIM trial).
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Melanoma is the fifth and sixth most common cancer in men and
women, respectively, and has the fastest growing incidence of any cancer
[1]. First-line treatment for non-metastatic melanoma is, when possible,
surgical excision of the primary tumor and affected lymph nodes, with
eventual adjuvant radiation therapy (RT) [2,3]. Melanoma is
characterized by symptomatic locoregional recurrence, distant metas-
tases, and despite recent advances, poor response to systemic drugs [4].
Although RT is important for locoregional control and palliation in
oncology, this approach is not always incorporated into the
management of melanoma. Reluctance to use RT can be traced
to findings of early experimental and clinical reports suggesting that
Figure 1. Schematic overview of the mechanism of action of Dbait.
In irradiated and Dbait-treated cells, DNA repair signaling is
perturbed leading to global inhibition of DNA repair pathways. On
the one hand, Dbait recognition by the DNA-PK complex induces
DNA-PK activation ( ) and initiates the uncoordinated phosphor-
ylation of its nuclear targets visualized by pan-nuclear γ-H2AX ( ).
Upon creation of a DSB in the DNA, the DNA damage signaling
apparatus induced by Dbait is dispersed across all the modified
chromatin and inhibits the recruitment of the factors required for
DSB repair at the site of the damage. This leads to both non-
homologous end joining (NHEJ) and homologous recombination
(HR) inhibition. On the other hand, Dbait can also be bound by
PARP (major protein involved in BER and SSBR) leading to its
autoPARylation and the further recruitment of different BER and
SSBR proteins on Dbait molecules. These proteins are thus
hijacked far from the damage leading to BER/SSBR inhibition.
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described as “futile” [7] and “should not be relied on for the cure of
these lesions” [8]. In the early 1970s, in vitro studies revealed that
melanoma cells are less sensitive to RT only at lower doses and show
increased cell death with higher doses per fraction [9]. In the
modern era, many reports have demonstrated that RT could have a
potential place in the management of melanoma (e.g., post-
lymphadenectomy, brain metastases, and so on) although contro-
versy remains [10]. Most studies use a hypofractionated (dose per
fraction N 2.5 Gy) schedule of RT. Greater use of RT, especially in
association with molecular therapy that could enhance its efficacy,
may allow substantial improvements to multidisciplinary melanoma
management [10,11].
RT cytotoxicity is mainly due to DNA damage. DNA double-strand
breaks (DSBs) are the most severe RT-induced DNA damage and are
lethal to the cell if not repaired [12]. DSBs are produced directly and
indirectly by RT. Indirect DSB most often occur during replication if
initial damage is unrepaired. For example, when a replication fork
encounters an unrepaired single-strand break (SSB), the fork is blocked
and leads to the conversion of this SSB in DSB [13]. The ability of
cancer cells to recognize DNA damage and initiate repair is an
important mechanism of radioresistance [14,15]. Inhibition of DNA
repair could make cancer cells more vulnerable to the DNA damaging
therapies like RT [16]. Therefore, to inhibit DNA repair, we designed
an innovative family of molecules named Dbait (which stands for DNA
strand break bait). Dbait consists of 32 bp deoxyribonucleotides
forming an intramolecular DNA double helix that mimics DNA
lesions. They act as a bait for DNA damage signaling enzymes, the poly-
adenyl-ribose polymerase (PARP), and the DNA-dependent kinase
(DNA-PK), inducing a “false” DNA damage signal and ultimately
inhibiting recruitment at the damage site of many proteins involved in
DSB and SSB repair (SSBR) pathways (Figure 1) [17,18].
We report an analysis of the potential of Dbait for clinical
application to sensitize skin melanoma to RT. First, we demonstrated
the radiosensitizing properties of Dbait in vitro. Then, we performed
animal studies to determine the clinical potential and applicability of
combined Dbait + RT treatment for human melanoma. The data
presented here were used to design the clinical trial DRIIM
(clinicaltrials.gov/ct2/show/NCT01469455).
Material and Methods
Cell Culture and Dbait Molecules
The human skinmelanoma cell lines SK28 and 501mel were obtained
fromAmerican TypeCulture Collection (ATCC) (Manassas, VA). Cells
were grown in complete RPMI (Gibco, Cergy Pontoise, France)
supplemented with 10% FBS (ATGC, Orléans, France), 1% sodium
pyruvate, streptomycin (100 mg/ml), and penicillin (100 mg/ml;
Invitrogen, Carlsbad, CA). Cells were maintained at 37°C under a
5% CO2 atmosphere, at 100% humidity. Dbait molecules are 32 bp
oligonucleotides that are made by automated solid-phase oligonucle-
otide synthesis methods (Eurogentec, Seraing, Belgium). The sequence
of the Dbait molecule used is 5′-GCTGTGCCCACAACCCAG
CAAACAAGCCTAGA-(H)-TCTAGGCTTGTTTGCTGG
GTTGTGGGCACAGC-3′, where H is a hexaethylene glycol linker
and the underlined letters are phosphorodiamidate nucleosides. For
animal studies, a 5′-cholesterol linked form of Dbait (called DT01),
which avoids the use of toxic transfection agents, diluted in 5% glucose
was used [19].In Vitro Dbait and Irradiation Treatments and Clonogenic
Survival Assay
DT01 used in vivo does not efficiently transfect cells in vitro.
Therefore, we used 1.25 mg/l Dbait, or transfection control,
complexed with 11 kDa polyethylenimine (PEI; Polypus Transfec-
tion, Illkirch, France) to treat the cells. Cells were seeded at 300,000
cells per 60-mm dishes the day before transfection. Then, cells were
transfected with Dbait or control in 1200 μl of serum-free RPMI for
5 hours. At the end of transfection, the medium was removed and
replaced with complete RPMI (Gibco) already heated to 37°C. The
irradiation was then performed as single exposures at increasing doses
(1- to 8-Gy irradiation), delivered by a 137Cs unit (0.5 Gy/min).
Twenty-four hours after irradiation, cells were seeded at 100 to
10,000 cells per 25-cm3 flask in complete medium. After 12 days of
incubation, the cell clones were stained with crystal violet. Colonies
with more than 50 cells were counted by microscopic inspection and
the radiation-surviving fractions were determined. The intrinsic
radiosensitivity was evaluated by using two parameters: the surviving
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curves were obtained in accordance with the linear quadratic model
(Kaleida Graph software 4.0).
Antibodies and Immunologic Techniques for H2AX Labeling
SK28 and 501mel cells were seeded at 300,000 cells per 60-mm
dishes, 24 hours before treatment. Cells were transfected by incubation
with 1.25 mg/l Dbait or transfection control for 5 hours. When
irradiated, the cells were then subjected to 2.5-Gy irradiation.
Immunocytochemistry of the phosphorylated form of the H2AX
histone (γ-H2AX) was done as previously described [18] immediately
after irradiation and/orDbait treatment.Monoclonal antibodies against
γ-H2AX (Millipore, Billerica, MA) were used. Microscopy was
performed at room temperature with the Leica SP5 confocal system,
attached to a DMI6000 stand, with a 40 or 63×/1.4 oil immersion
objective. Images were processed with the freely available ImageJ
software (http://rsb.info.nih.gov.gate1.inist.fr/ij/) and the LOCI bio-
format plug-in (http://www.loci.wisc.edu/ome/formats.html) to access
images generated by the Leica SP5 confocal system.
Assessment of DNA Breaks by Single-Cell Electrophoresis
SK28 and 501mel cells were seeded at 100,000 cells per 35-mm
dishes. Twenty-four hours later, cells were transfected with 1.25 mg/l
Dbait or control for 5 hours and were left untreated or were treated
with 8-Gy irradiation. DNA breaks were assessed by single-cell
electrophoresis (alkaline Comet assay) immediately, 5, 30, 60, and
180 minutes and 24 hours after irradiation, as previously described
[18]. DNA damage was quantified as the Comet tail moment, which
represents the extent of DNA damage (both SSB and DSB) in
individual cells.
Assessment of Dbait Activity in DNA-PK Inhibited or
Depleted Cells
SK28 cells were seeded in six-well plates at a concentration of 1.5 × 105
cells on the day before shRNA transduction to obtain 50% of confluence
for the viral infection. Subconfluent SK28 cells were transduced with
lentiviruses that expressed either the control, non-targeting shRNA
(shCTL; sc-108080; Santa Cruz Biotechnology, (Dallas, Texas, USA)),
or shRNA targeting DNA-PKcs (shDNA-PK; sc-35200-V; Santa
Cruz Biotechnology) at a multiplicity of infection of 3 using polybrene
(5 μg/ml). The most efficiently depleted cells (80% of knockdown of
DNA-PKcs gene) were selected; 300,00 cells were seeded in 60-mm
dishes. Twenty-four hours later, cells were transfected by incubation
with 1.25 mg/l Dbait or transfection control for 5 hours. Immediately
after treatment, cells were immunostained with mouse monoclonal
anti–DNA-PKcs (Ab-4, Cocktail; Thermo Scientific, (Waltham, MA,
USA)) or mouse monoclonal anti–γ-H2AX antibodies (Millipore) and
counterstained with 4',6-diamidino-2-phenylindole (DAPI). For
DNA-PK inhibition, cells were incubated for 1 hour in serum-free
medium containing 25 μMNU7026 and then incubated in serum-free
medium containing 25 μM NU7026 and 1.25 mg/l control or Dbait
for 5 hours. Immunocytochemistry of the phosphorylated form of
γ-H2AX was conducted immediately after control or Dbait treatment.
Dbait and Irradiation Treatment in Mice
SK28 human melanoma xenograft tumors were obtained by
injecting 4 × 106 tumor cells into the flank of adult female nude mice
(Janvier, Le Genest Saint Isle, France). The animals were housed in
our animal facility for at least 1 week before starting the experiments.
There were six animals per cage under controlled conditions of lightand dark cycles (12 hours:12 hours), relative humidity (55%), and
temperature (21°C). Food and tap water were available ad libitum.
When subcutaneous tumors reached approximately 125 mm3, mice
were separated into homogeneous groups to receive different
treatment protocols: no treatment (NT), RT alone for 2 weeks
(RT2w: 10 × 3 Gy), RT alone for 4 weeks (RT4w: 20 ×3 Gy), DT01
alone for 2 weeks (DT012w: 6 × 4 mg), RT + DT01 for 2 weeks
(RT2w + DT012w: 10 ×3 Gy + 6 × 4 mg) or 4 weeks (RT4w +
DT014w: 20 ×3 Gy + 12 × 4 mg), and RT + DT01 followed by a
second cycle of DT01 alone 6 weeks later (RT2w + DT012w +
DT012w: 10 ×3 Gy + 6 × 4 mg + 6 × 4 mg). Initially, we checked
mock-treated animals to ensure the absence of any changes in tumor
growth or survival compared to animals treated with or without RT
(Figure S1). A 137Cs unit (0.5 Gy/min) with a shield designed to
protect approximately two thirds of the animal’s body was used to
administer RT. Doses were controlled by thermoluminescence
dosimetry. Four milligrams of DT01 was given 5 hours before RT
sessions (2 mg intratumoral and 2 mg peritumoral subcutaneous
injections), once every 2 days. All animals were treated daily with
chloroquine per os (40 mg/kg), for 1 week before DT01 treatment
and then during the whole treatment period. Administration of
chloroquine favors the release of oligonucleotides, like DT01, from
endosomes into the cytoplasm improving its cellular uptake [19,20].
In all experiments, tumors were measured with a digital caliper every 2
to 3 days and any local skin toxicity was noted. Tumor volumes were
calculated using the following formula: length × width × width/2.
Mice were weighed every week and followed up for 280 days. For
ethical reasons, the animals were sacrificed when tumors reached
1500 mm3. The Local Committee on Ethics of Animal Experimen-
tation approved all experiments.
Micronuclei Assessment
Micronuclei contain fragments of chromosomes generally gener-
ated during defective DNA repair [21]. One month after initial
treatment, tumors were fixed in formalin and then embedded in
paraffin. Sections were cut and stained with hematoxylin, eosin, and
saffron. Percent of micronuclei was estimated in the non-necrotic and
proliferative area by quantifying the cells presenting micronuclei in
the cytoplasm, according to their described characteristics [22] in at
least 1000 cells.
Statistical Analysis
Random-effects model was used for comparison between clonogenic
cell survival assays [23]. The type of interactionwas described as additive
when corresponding to the effect being equal to that of the theoretically
calculated effects of RT or Dbait alone and supra-additive when the
effect of concurrent use of both RT and Dbait is considered to be more
efficient than the calculated effect of single use. The term synergy is
considered to correspond to supra-additivity [24]. Two-sided unpaired
t tests were used for comparison between micronuclei formation and
tumor growth delay (TGD). Comet tail moment data were analyzed as
previously described [25], by two-way analysis of variance of the
medians, followed by Bonferroni post hoc tests. TGD was calculated by
subtracting the mean tumor volume quadrupling time of the control
group from tumor volume quadrupling times of individual mice in each
treatment group. The mean TGD was calculated for each treatment
group from the individual measurements. Survival curves were assessed
by Kaplan-Meier estimates and compared using the nonparametric
log-rank test since the data do not follow a normal distribution.
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statEL (Ad Science, (Paris, France)) were used for statistical analyses.
Results
Dbait Disorganizes and Inhibits Repair of Radio-Induced
DNA Damage in Melanoma Cell Lines Leading to Inhibition
of Proliferation
We have previously shown that Dbait treatment led to the
activation of DNA-PK [17]. This hyperactivation triggers phosphor-
ylation of the histone H2AX all along the chromatin, however not
specifically at radio-induced DSB sites. This disorganized H2AX
phosphorylation prevents subsequent detection of the radio-induced
DSBs and therefore their repair (Figure 1). Here, we checked the
ability of Dbait to induce DNA-PK activation in the melanoma cellFigure 2. Effect of Dbait on H2AX phosphorylation. (A) SK28 and 5
oligonucleotide or Dbait ± NU7026 (DNA-PK inhibitor). Immunofluore
Dbait treatment led to non-localized pan-nuclear H2AX phosphorylatio
activation. Bar, 50 μm. (B) SK28 melanoma cells were transfected wit
of γ-H2AX (red) and chromatin (DAPI; blue) was visualized immediately
localized γ-H2AX foci representing radio-induced DNA DSBs; Dbait tr
H2AX phosphorylation evidencing Dbait activity. Bar, 30 μm. (C) SK28
non-targeting shRNA, or shRNA targeting DNA-PKcs. After Dbait tran
DNA-PKcs or anti–γ-H2AX. Dbait activity was not detected in cells tralines SK28 and 501mel by monitoring the H2AX phosphorylation.
Dbait treatment, with or without RT, resulted in pan-nuclear
phosphorylation of H2AX in at least 60% of the cells, evidencing
DNA-PK activation by Dbait in these cells (Figure 2A). The Dbait-
induced H2AX phosphorylation displays a characteristic pan-nuclear
distribution different from the γ-H2AX foci formed at the radio-
induced DNA DSB (Figure 2B). There were no such signals in the
shDNA-PK mutants or in cells with inhibited DNA-PK (Figure 2, A
and C), demonstrating that H2AX pan-nuclear phosphorylation was
strictly dependent on DNA-PK activation by Dbait.
The consequences on clonogenic cell survival of Dbait treatment
associated to RT were investigated in 501mel and SK28 cells. Survival
analyzed 12 days after treatment revealed a high sensitivity of 501mel
to stand-alone treatment of Dbait with only 35% of cells forming01mel melanoma cells were transfected with an inactive control
scence of γ-H2AX (red) and chromatin (DAPI; blue) was visualized.
n evidencing Dbait activity. This activity was dependent on DNA-PK
h an inactive control oligonucleotide or Dbait. Immunofluorescence
after irradiation and/or Dbait treatment. Irradiation alone resulted in
eatment with or without irradiation led to non-localized pan-nuclear
cells were transduced with lentiviruses that express either control,
sfection, cells were immunostained with mouse monoclonal anti–
nsduced with shRNA targeting DNA-PKcs. Bar, 50 μm.
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cells were less affected by Dbait treatment alone with 85% of cells
forming colonies. Similarly, melanoma cells showed different
sensitivities to RT. SK28 cells were more radioresistant than
501mel (surviving fraction at 2 Gy, 0.89 vs 0.61; area under the
survival curve, 5.2 vs 3.6). However, both cell lines demonstrated an
increased lethality after combined treatment compared to irradiation
alone (P b .001; Figure 3, A and B). In 501mel cells, association of
Dbait + RT led mainly to an additive increase of cell toxicity, while
highly RT-resistant SK28 cells were significantly radiosensitized with
combined treatment for all RT doses (P b .001). Interestingly, a loss
of the initial shoulder region of the curve was observed in the SK28-
radiosensitized cell line (Figure 3A).Figure 3. Effect of Dbait on cell survival and repair of DNA breaks ind
cells were irradiated with 1 to 8 Gy, and clonogenic survival was est
Dbait and irradiation on cell survival. Data are represented as med
transfected cells was analyzed by alkaline Comet assay at various t
treatment and at various times (0, 5, 30, 60, and 180 minutes and 24
cell lines.To confirm that radiosensitization by Dbait was due to the
inhibition of repair of radio-induced DNA SSB and DSB damage, we
carried out alkaline Comet assays (Figure 3C). Dbait treatment alone
did not induced DNA damage in both cell lines. In SK28 control–
transfected cells, RT induced DNA damage, which gradually
decreased over time due to repair activity. In contrast, in Dbait-
treated cells, RT-induced DNA damage was not initially greater, but
persisted for longer (P b .05) as expected if break repair was inhibited.
While displaying greater radiosensitivity compared to SK28, 501mel
shows rapid DNA repair, which was only slightly reduced by Dbait
treatment. The damage repair revealed by the Comet assay could be
less accurate in 501mel cells and responsible for the late death revealed
by the low clonal survival.uced by RT. (A) Cell survival assay. Transfected SK28 and 501mel
imated 12 days later. (B) Simulation of expected additive effect of
ian values ± standard error. (C) The extent of DNA damage in
imes (0, 60, and 180 minutes and 24 hours) after Dbait or control
hours) after combination with irradiation (8 Gy) in SK28 and 501mel
Table 1. Comparison of the Response to Treatment of SK28 Melanoma Xenografted Animals
Treated with Various Protocols.
Treatment Number
of Mice
Median
Survival
in Days
RR
(P Value)
Mean TGD
in Days (%)
SD TGD
in Days
Complete
Response (%)
NT 21 57 0 (100) 11 0 (0)
DT012w 10 81 0.48 (3 × 10
−2) 11 (149) 10 0 (0)
RT2w 18 67 0.41 (2 × 10
−3)† 10 (147) 16 0 (0)
RT2w + DT012w 12 119 0.38 (4 × 10
−3)‡ 57 (362) 18 0 (0)
RT2w + DT012w +
DT012w
18 150 0.21(5)§ 75 (449) 76 4 (22)
RT4w 12 109 0.24 (5)
¶ 39 (278) 44 1 (8)
RT4w + DT014w 11 221 0.19 (5)
# 126 (681) 52 7 (64)
RR, relative risk. Statistics: DT012w versusNT,
†RT2w versusNT,
‡RT2w +DT012w versusRT2w,
§RT2w +
DT012w + DT012w versus RT2w + DT012w,
¶RT4w versus NT,
#RT4w + DT014w versus RT4w.
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RT Protocol
We used athymic nude mice bearing SK28 melanoma tumor
xenografts to investigate whether the radiosensitizing effect observed
in vitro was also reproducible in vivo. SK28 xenografts were chosen
since they were more radioresistant in vitro. The experimental design
was aimed at confirming the clinical relevance and applicability of the
approach (Figure 4A). Consistent with one of the current palliative
RT protocols used for patients, 10 fractions of 3 Gy were given locally
over a 2-week period. DT01 was administered locally 5 hours before
RT every 2 days (six sessions in total; Figure 4A). Tumor growth was
slightly lower following RT2w or DT012w treatments alone than in
untreated animals. However, the combination of the two treatments
(RT2w + Dbait2w) significantly decreased tumor growth (P b .004 vs
RT2w or DT012w; Figure 4B and Table 1). Moreover, the RT2w +
DT012w combined therapy resulted in a significant enhancement of
survival (P b .01 vs RT2w or DT012w; Figure 4C and Table 1). To
maintain treatment efficacy, we added a second cycle of DT01
administration at the time of tumor escape, 6 weeks after the initial
RT2w + DT012w treatment. The second cycle of DT01 alone
significantly improved the control of tumor growth leading to an
enhanced survival (P b .0001 vs RT2w + DT012w; Figure 4C and
Table 1). Moreover, this additional treatment triggered a complete
response in 4 of the 18 animals (22%; Table 1). Importantly, no
significant increase in skin toxicity was observed in irradiated and
Dbait-treated healthy tissues surrounding the tumor during follow-up.
To confirm that DT01 treatment inhibits DNA repair in vivo, we
monitored micronuclei formation in the proliferative area of the
treated tumors. Micronuclei are small additional nuclei, located in the
cytoplasm, that contain fragments of chromosomes largely generated
during defective DNA repair [21]. As expected after DNA repairFigure 4. Radiosensitization of SK28 tumors by DT01 with a “palliative
xenografts were untreated (NT), treated for 2 weeks with 10 fractions
of DT01 (DT012w), both treatments (RT2w + DT012w), or both treatm
DT012w + DT012w). (A) Treatment schedule. Each RT 3-Gy fraction is
represented by a gray triangle. (B) Tumor growth. DT01 with RT sig
monitored until tumors reached 1500 mm3 (death time). Survival wa
RT2w + DT012w + DT012w. Vt, tumor volume at a given time point; Vinhibitor treatment, there were twice as many micronuclei formed in
cells following RT2w + DT012w treatment than RT2w or DT012w
alone (P b .03; Figure 5).
Radiosensitizing Effect of Dbait In Vivo with a “Radical”
RT Protocol
The RT protocol (10 ×3 Gy) used in the experiment reported
above is a palliative protocol proposed to patients suffering from non-
operable cutaneous melanoma. We further investigated whether
Dbait could increase the efficacy of a more “radical” RT protocol. We
performed the treatment cycle over 4 weeks, such that the total doses
were 20 ×3 Gy of irradiation (biologic equivalent dose of 37 ×2 Gy
using a linear quadratic model and α/β = 2.5 [26]) and 12 × 4 mg of
Dbait (Figure 6A). RT4w + Dbait4w significantly extended TGD to
39 days versus 10 days for RT2w + Dbait2w (Figure 6B; P b .01),
resulting in doubling the median survival (221 vs 119 days; P b .0001;” RT protocol. Mice bearing subcutaneous SK28 melanoma tumor
of 3 Gy (RT2w), treated for 2 weeks with six administrations of 4 mg
ents followed with a second cycle of DT01 6 weeks later (RT2w +
represented by a black triangle. Each DT01 4-mg administration is
nificantly increased tumor growth control. (C) Survival. Mice were
s significantly improved in mice treated with RT2w + DT012w and
i, initial volume before treatment.
Figure 5. Micronuclei detection in SK28 melanoma tumor xenografts treated with a “palliative” RT protocol. One month after initial
treatment by RT2w, DT012w, and RT2w + DT012w according to the “palliative” protocol (Figure 4), tumors were removed and the numbers
of micronuclei were quantified. Percentage of micronucleus was estimated in the non-necrotic and proliferative area by quantifying the
cells presenting micronucleus in the cytoplasm within at least 1000 cells. (A) Results are reported as mean (±standard error)
percentages. There were twice as many micronuclei formed in cells following RT2w + DT012w treatment than RT2w or DT012w treatments
(P b .03). (B) Representative images of hematoxylin, eosin, and safran labeled tumor sections with micronuclei detection (arrows).
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complete responses among the 11 animals treated (64%; Table 1). As
previously observed, doubling the RT and Dbait doses was not
associated with additional local adverse effects.
Discussion
Efficient DNA repair activity in cancer cells increases the resistance of
cancer to RT [27,28]. Over the last decade, many moleculesFigure 6. Radiosensitization of SK28 tumors by DT01 with a “radical
xenografts were untreated (NT), treated for 4 weeks with 10 fractions
(RT4w +DT014w). (A) Treatment schedule. Each RT 3-Gy fraction is rep
represented by a gray triangle. (B) Tumor growth. DT01 with RT sig
monitored until tumors reached 1500 mm3 (death time). Survival wa
tumor volume at a given time point; Vi, initial volume before treatmeinhibiting various DNA repair pathways by targeting their key
enzymes have been developed [29–33]. These strategies, based on
specific target inhibition, may be thwarted by target mutation or
activation of another repair pathway. For example, PARP inhibitors
require an additional defect in homologous recombination to be
effective [29]. In contrast, Dbait is not a specific enzyme inhibitor but
represents a new drug strategy targeting the entire DNA DSB repair
system through perturbation of DNA repair signaling [17,18]. On” RT protocol. Mice bearing subcutaneous SK28 melanoma tumor
of 3 Gy (RT4w), or treated with combined RT and DT01 treatments
resented by a black triangle. Each DT01 4-mg local administration is
nificantly increased tumor growth control. (C) Survival. Mice were
s significantly improved in mice treated with RT4w + DT014w. Vt,
nt.
842 Dbait with Radiotherapy to Treat Melanoma Biau et al. Neoplasia Vol. 16, No. 10, 2014the one hand, the DNA DSB signaling apparatus induced by Dbait is
dispersed across all the modified chromatin and inhibits the
recruitment of the factors required for DSB repair at the site of
damage. However, Dbait can also be bound by PARP [major protein
involved in base excision repair (BER) and SSBR] leading to its
autoPARylation and further recruitment of different BER and SSBR
proteins on Dbait molecules. These proteins are thus hijacked far
from the site of damage leading to BER/SSBR inhibition [34].
In this preclinical study, Dbait was used to radiosensitize human
melanoma both in vitro and in vivo. In vitro, Dbait led to an increase
of cell toxicity in both cell lines. This increase was additive in one cell
line and synergic in the other. Although a synergic effect is preferred
for radiosensitization, both additive and synergic effects can be of
clinical interest, particularly if the molecule is not toxic for healthy
tissues, which is the case for Dbait in this preclinical study.
Interestingly, the synergic effect was observed in the cell line that
was found to be the more radioresistant. In this cell line, the shoulder
region of the survival curve was no longer observed with the
combined treatment. This could be consistent with Dbait mechanism
of action as this part of the curve is often described as representative of
the capacity of DNA repair of the cells [35–37]. For the in vivo
portion of the work, the experimental design was intended to test the
clinical relevance and applicability of these findings, both for the
palliative RT protocol and local administration of DT01. A recent
review reported the potential applications of intralesional agents in
the management of cutaneous malignancy [38]. There have also been
reports of intralesional injection of accessible melanoma tumors with
standard chemotherapeutic agents (cisplatin and bleomycin) and with
drugs generating a local immune response [39–42]. Similarly, the
association of intralesional injections and subsequent RT has been
assessed in the management of accessible metastatic or recurrent
melanoma [43,44]. Here, we found that for some tumors with
necrosis or high interstitial pressure, it was preferable to administer
DT01 locally at the periphery of the tumor to favor delivery to the
proliferative area. Therefore, we combined both intratumoral and
peritumoral injections for DT01 administration. This design had the
advantage of healthy tissue at the periphery of the tumor receiving
both DT01 and RT and therefore a good indicator of healthy skin
tolerance of combined treatment (Supplementary Figure S2).
The antitumor activity of Dbait in association with RT has already
been demonstrated [18,19]. However, it has been observed that Dbait
without transfectants or modifications had no antitumor activity as it
did not enter into the tumor cells. Although Dbait complexed with
PEI formulations displayed a strong antitumor activity, they revealed
a weak effective dose/toxicity ratio of 0.8 with healthy skin necrosis
due to the transfection agent (PEI). The necessity of using toxic
transfection agents prevented progress toward clinical applications. In
this study, we used an innovative formulation of Dbait, linked to
cholesterol (DT01), which is efficiently taken up by tumor cells in the
absence of adjuvant vectors [19,45] and, therefore, could be proposed
to patients. In vivo, DT01 seems as effective as Dbait linked with PEI
but much less toxic. DT01 is a novel chemical family, belonging to
the oligonucleotide pharmacological class. DT01 toxicology studies
in Wistar rats and cynomolgus monkeys show that the only
undesirable adverse effects observed are inflammatory responses at
the injection sites that were slight to moderate, dose-dependent, and
reversible after a 2-week recovery period [46]. DT01 administration
in mice does not increase the sensitivity of healthy tissue surrounding
the tumor to irradiation. As Dbait does not induce cell cycle arrest inmelanoma cell lines (Supplementary Figure S3)[17], the specificity of
action of DT01 in tumor cells may be due to the impaired cell cycle
controls (checkpoints) frequent in tumor cells that allow cells to
divide despite DT01 consequent unrepaired breaks and therefore
enter mitotic catastrophe. This impaired cell cycle controls are often
associated with p53 mutations [47]. In contrast, non-tumor cells with
proficient cell cycle control stop dividing until repair completion,
which can take place after DT01 disappearance [48]. Therefore,
DT01 simply prevents DNA repair of RT-induced damage without
inducing new lesions on chromosomes, leading to toxicity of dividing
tumor cells and not of healthy tissues.
Here, we demonstrate that DT01 exhibited a moderate stand-
alone antitumor activity, which could be explained by an
accumulation of unrepairable spontaneous DNA breaks during cell
proliferation as suggested by the presence of micronuclei in tumors.
Conversion of this basal damage and replication stress into severe lesions
(unrepaired DSB) by DT01-induced DNA repair inhibition might
trigger cell death and thus the moderate stand-alone activity of the
molecule. When the treatments were combined, DT01 improved RT
efficacy leading to a pronounced increase in animal survival. In patients,
in case of recurrence in an already irradiated zone, a second full cycle of
treatment combining RT + Dbait will not be feasible. We therefore
tested additional DT01 treatment alone: this led to a longer control of
tumor growth and, in some cases, even complete response. The tumor
growth control combined to micronuclei assessment, 50 days after the
first treatment cycle, showed that the first RT + DT01 treatment
triggered long-term tumor genetic instability conferring dependency of
the tumor to constitutive repair activities [49–51]. This dependency
could sensitize the tumor cells to a second cycle with a stand-alone
DT01 treatment. These findings suggest that it may be valuable to
repeat Dbait administration after the initial irradiation.
Our results provide the preclinical proof of concept that combining
RT with DT01 inhibition of DNA repair could be of benefit to
patients with cutaneous melanoma. A first-in-human phase I trial
(DRIIM: clinicaltrials.gov/ct2/show/NCT01469455) is currently
under way to evaluate the tolerance and efficacy of local DT01
administration in association with RT in patients suffering from in-
transit metastases of melanoma. DT01 and RT are delivered
according to the palliative protocol described in this manuscript.
Patients who show treatment-associated benefits may be proposed an
additional course of DT01 treatment after the end of follow-up. If
DT01 safety and efficacy are confirmed, the preclinical results we
report suggest that a clinical trial with more radical doses of RT and
DT01 could be considered. This approach may provide an innovative
option for neoadjuvant or radical treatment strategies for inoperable,
locoregional, newly diagnosed, or recurrent melanoma.
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